Bota Biosciences

bota.bio

Bota_Biosciences
Bota Bio is an industrial synthetic biotechnology company with a vision to program biological systems for clean and efficient bio-manufacturing of common household and industrial products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

REGENERON TO ACQUIRE DECIBEL THERAPEUTICS, STRENGTHENING GENE THERAPY AND HEARING LOSS PROGRAMS

Globenewswire | August 10, 2023

news image

Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc. a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement for the acquisition of Decibel by Regeneron at a price of $4.00 per share of Decibel common stock payable in cash at closing, with an additional non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achieveme...

Read More

Medical, Industry Outlook

QURALIS AND UNLEARN ANNOUNCE COLLABORATION TO ACCELERATE AND OPTIMIZE ALS CLINICAL TRIALS WITH GENERATIVE ARTIFICIAL INTELLIGENCE TECHNOLOGIES

PRNewswire | June 28, 2023

news image

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, and Unlearn, a pioneering technology company innovating machine learning to revolutionize medical research, today announced they have entered into a collaboration to accelerate and optimize QurAlis' clinical program in ALS with Unlearn's advanced generative artificial ...

Read More

Cell and Gene Therapy

MISSION BIO DEVELOPS SINGLE-CELL SOLUTION TO ADDRESS CHALLENGES IN GENOME EDITING

PR Newswire | May 12, 2023

news image

Mission Bio, the single-cell DNA and multi-omics company, announced today the Tapestri® Genome Editing Solution, an end-to-end product for genome editing analysis. The product will be previewed next week at the American Society of Gene and Cell Therapy Conference (ASGCT) 26th Annual Meeting. By enabling robust single-cell insights impacting both efficacy and safety, the solution will be a powerful analytical tool for developing the next generation of gene-edited therapies. T...

Read More

Cell and Gene Therapy, Industrial Impact

BIO-TECHNE ANNOUNCES COMPLETION OF AND GENE THERAPY CATAPULT ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

Bio-Techne Corporation | March 20, 2023

news image

Bio-Techne Corporation announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technolog...

Read More
news image

Medical

REGENERON TO ACQUIRE DECIBEL THERAPEUTICS, STRENGTHENING GENE THERAPY AND HEARING LOSS PROGRAMS

Globenewswire | August 10, 2023

Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc. a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement for the acquisition of Decibel by Regeneron at a price of $4.00 per share of Decibel common stock payable in cash at closing, with an additional non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achieveme...

Read More
news image

Medical, Industry Outlook

QURALIS AND UNLEARN ANNOUNCE COLLABORATION TO ACCELERATE AND OPTIMIZE ALS CLINICAL TRIALS WITH GENERATIVE ARTIFICIAL INTELLIGENCE TECHNOLOGIES

PRNewswire | June 28, 2023

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, and Unlearn, a pioneering technology company innovating machine learning to revolutionize medical research, today announced they have entered into a collaboration to accelerate and optimize QurAlis' clinical program in ALS with Unlearn's advanced generative artificial ...

Read More
news image

Cell and Gene Therapy

MISSION BIO DEVELOPS SINGLE-CELL SOLUTION TO ADDRESS CHALLENGES IN GENOME EDITING

PR Newswire | May 12, 2023

Mission Bio, the single-cell DNA and multi-omics company, announced today the Tapestri® Genome Editing Solution, an end-to-end product for genome editing analysis. The product will be previewed next week at the American Society of Gene and Cell Therapy Conference (ASGCT) 26th Annual Meeting. By enabling robust single-cell insights impacting both efficacy and safety, the solution will be a powerful analytical tool for developing the next generation of gene-edited therapies. T...

Read More
news image

Cell and Gene Therapy, Industrial Impact

BIO-TECHNE ANNOUNCES COMPLETION OF AND GENE THERAPY CATAPULT ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

Bio-Techne Corporation | March 20, 2023

Bio-Techne Corporation announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technolog...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us